For some patients with liver cancer, surgery may not be an option. CentraState now offers transarterial radioembolization (TARE), an advanced therapy that targets tumors with a high dose of focused radiation while sparing surrounding healthy tissue.
Approximately 34,000 people are diagnosed with liver cancer in the United States each year, according to the Centers for Disease Control and Prevention. Surgery isn’t always recommended for patients with hepatocellular carcinoma, the most common type of liver cancer. TARE is an effective, minimally invasive treatment option for certain cancer patients, including those who aren’t able to undergo a liver transplant or liver resection or have an intolerance to anesthesia.
The targeted procedure, which doesn’t require general anesthesia, is performed by board-certified interventional radiologists Seth Stein, MD, Michael D’Angelo, MD, and Theresa Aquino, MD, specialists in interventional oncology. As part of a multidisciplinary team that includes medical oncologists, radiation oncologists, surgeons, and gastroenterologists, they determine unique cancer treatment plans for each patient. And while TARE isn’t a cure for every patient, the procedure can prolong—and greatly improve—lives of those with cancer.
“Cancer is increasingly becoming a disease that people live with,” Dr. D’Angelo says. “When we slow its progression, patients enjoy a better quality of life.”